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Abstract
Background: Light chain amyloidosis (AL) is a rare but often fatal disease due to intractable heart
failure. Amyloid deposition leads to diastolic dysfunction and often preserved ejection fraction. We
hypothesize that AL is associated with regional systolic dyssynchrony. The aim is to compare left
ventricular (LV) regional synchrony in AL subjects versus healthy controls using 16-segment
dyssynchrony index measured from 3-dimension-al (3D) echocardiography.
Methods: Cardiac 3D echocardiography full volumes were acquired in 10 biopsy-proven AL
subjects (60 ± 3 years, 5 females) and 10 healthy controls (52 ± 1 years, 5 females). The LV was
subdivided into 16 segments and the time from end-diastole to the minimal systolic volume for each
of the 16 segments was expressed as a percent of the cycle length. The standard deviations of these
times provided a 16-segment dyssynchrony index (16-SD%). 16-SD% was compared between
healthy and AL subjects.
Results: Left ventricular ejection fraction was comparable (control vs. AL: 62.4 ± 0.6 vs. 58.6 ±
2.8%, p = NS). 16-SD% was significantly higher in AL versus healthy subjects (5.93 ± 4.4 vs. 1.67 ±
0.87%, p = 0.003). 16-SD% correlated with left ventricular mass index (R 0.45, p = 0.04) but not to
left ventricular ejection fraction.
Conclusion:  Light chain amyloidosis is associated with left ventricular regional systolic
dyssynchrony. Regional dyssynchrony may be an unrecognized mechanism of heart failure in AL
subjects.
Background
Light chain amyloidosis (AL) is a rare multiorgan disease
with extracellular deposition of fibrillar amyloid proteins
derived from immunoglobulin light chains [1,2]. Amy-
loid deposits in the heart, kidneys, liver and nervous sys-
tem cause organ failure. There is poor prognosis with
median survival of 4 months with heart failure [3,4]. It is
associated with diastolic dysfunction but often preserved
left ventricular (LV) ejection fraction, especially in the
early stages [5-9]. Left ventricular dyssynchrony is com-
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mon in heart failure patients and may contribute to its
pathophysiology [10]. Intraventricular dyssynchrony
reduces ventricular efficiency and cardiac performance
[11] while cardiac resynchronization therapy improves
symptoms and prolongs life [12,13]. Amyloid deposition
can potentially alter regional cardiac mechanics. In a
recent paper, Bellavia, et al. reported that patients with
less advanced AL cardiac amyloidosis had increased seg-
mental dyssynchrony compared to controls, but more
advanced amyloidosis was associated with hypersynchro-
nization using Doppler tissue velocity imaging [14]. Three
dimensional (3D) assessment of regional dyssynchrony
has potential advantage over 2-dimensional based tissue
Doppler studies as the temporal relationships of all 16
segments can be related with ease. Recently, 3D echocar-
diography has been utilized to study the temporal pattern
of the dispersion in segmental ventricular volumes during
the cardiac cycle in the novel assessment of ventricular
dyssynchrony [11,15] The dispersion (expressed as stand-
ard deviation) of the duration/timing from beginning of
systole to the minimal systolic volume in the 16 different
regions of the left ventricle (16-SD%, normalized to cycle
length) has been shown to be a marker of dyssynchrony
that was associated with ventricular dysfunction [11,15].
We hypothesize that AL subjects have left ventricular dys-
synchrony compared to healthy controls. The aim of the
study was to compare 16-SD% in AL subjects versus
healthy controls.
Methods
Patient Population
Ten consecutive biopsy-proven AL subjects undergoing
workup at 1 institution and 10 healthy controls under-
went 3D echocardiography (60 ± 3 versus 52 ± 1 years, p
= NS; 5 females in each group). The diagnosis was initially
confirmed by biopsy for light chain amyloid in kidneys (n
= 4), cardiac (n = 3), bone marrow (n = 2), gastrointestinal
tract (1), fat pad, axillary mass (n = 1 each). Among AL
subjects, 7 had cardiac involvement as defined by cardiac
biopsy or subendocardial late gadolinium enhancement
on routine magnetic resonance imaging [16,17]. Three AL
subjects without cardiac biopsy or late gadolinium
enhancement on MRI had thickened anteroseptum or
increased left ventricular mass index on echocardiogra-
phy.
The study was approved by the local Institutional Review
Boards (IRB) and is in compliance with the Helsinki Dec-
laration. All healthy controls gave informed consent. 9 AL
subjects signed informed consent as part of a prospective
observational study of biopsy-proven AL subjects. 1 AL
subject who had tissue biopsy confirmation of the disease
at post-mortem did not provide informed consent and
waiver of consent authorization was obtained from the
IRB.
3D Echocardiography Imaging and Analysis
In all subjects, cardiac 3D full-volume datasets were
acquired from the apical window using either an IE33 or
Sonos 7500 echocardiograph and X3-1 and X4-2 full
matrix-array transducer (Philips Medical Systems, Bothell
WA). The full volume data sets consisted of 4 real-time
subvolumes acquired during 4 cardiac cycles that are sub-
sequently combined to create a full 3D pyramidal data set.
The data sets all had evaluable endocardial borders.
The 3D volume dataset were analyzed by software (QLAB
version 4.2, 3DQ Avanced, Philips Medical Systems, Both-
ell WA) similar to previously published procedure [11]. In
brief, 2-dimensional orthogonal planes representing the
standard apical 4-chamber, apical 2-chamber and LV
short axis were oriented to bisect the LV and incorporate
the true LV apex. Five anatomic landmarks were set that
included septal, lateral, anterior, inferior mitral annulus
and the apical endocardium in both beginning and end of
systole. The software then recreated a 3D model of the
endocardial border at beginning and end of systole using
automated border detection algorithm. Manual correc-
tion of endocardial border was done if necessary. The soft-
ware then performed volumetric analysis creating a cast of
the LV cavity throughout the cardiac cycle.
The LV was divided into 16 segments (excluding the apex)
as per American Society of Echocardiography recommen-
dations [18]. The volume of each segment was plotted as
a function of time throughout the cardiac cycle, with time
normalized to the cycle length and expressed as % R-R
interval to account for differences in heart rate. The time
from end of diastole (beginning of systole) and minimal
systolic volume was quantified for each segment and the
standard deviation of these times for the 16 segments (16-
SD%) was calculated. The 16-SD% has been previously
shown to be a reliable measure of dyssynchrony
[11,15,19].
Two investigators (RQM and LH) trained in 3D volume
analyses independently measured the 3D dataset blinded
to disease condition and measured the subjects in random
order. The first investigator repeated the measurement
greater than a week after the first measurement in random
order and still blinded to subject condition.
Left ventricular mass index (LVMI) was calculated by
Devereux's formula using the diastolic left ventricular
internal diameter, anteroseptal thickness and inferolateral
thickness [20]. Left atrial volume index was calculated
using area-length method as per American Society of
Echocardiography standards [21]. In AL subjects, the lat-
eral mitral annular velocity (E'), mitral inflow velocity (E)
and ratio (E/E') were obtained using standard pulsed
spectral Doppler echocardiography [22].Cardiovascular Ultrasound 2008, 6:40 http://www.cardiovascularultrasound.com/content/6/1/40
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Data Analyses and Statistics
Data are expressed as mean ± standard deviation. Contin-
uous variables were compared by unpaired Student's t-test
for normally distributed data -or Mann-Whitney rank-
sum test for non-normally distributed data. Correlation
analysis was performed using Pearson's correlation.
Intraobserver and interobserver agreement was assessed
using intraclass correlation coefficient (ICC) analyses and
method of differences by Bland-Altman. For the ICC, a
two-way mixed model absolute agreement type was used
[23]. In this analysis, ICC values less than 0.4 indicate
poor reproducibility, values between 0.4 to 0.75 indicate
good reproducibility and greater than 0.75 shows excel-
lent reproducibility [23,24]. Limits of agreement were
assessed by plotting the differences in the measurement of
16-SD% against the average values of the measurement as
described by Bland-Altman [25,26]. Analyses were per-
formed using SPSS 16.0.1 (SPSS Inc. Chicago IL). A two-
sided p-value less than 0.05 was used to denote statistical
significance.
Results
Eight AL patients had New York Heart Association func-
tional classification I, with 1 each presenting in Class III
and IV heart failure. Left ventricular ejection fraction was
62.4 ± 0.6% in control subjects and 58.6 ± 2.8% for AL (p
= NS) (Table 1). AL subjects had thicker anteroseptum,
increased left atrial volume index and tendency towards
increased left ventricular mass index. The lateral mitral
annular velocity (E') was 15.4 ± 9.2 cm/s and ratio of
mitral inflow velocity to E' (E/E') was 7.2 ± 3.3 in AL sub-
jects. Although E and E/E' data were not available in con-
trol subjects, the mean values of E' and E/E' in AL subjects
in addition to increased left atrial volume index are con-
sistent with diastolic dysfunction and increased left ven-
tricular filling pressures based on prior validation studies
[27-30]. Based on conventional evaluation of degree of
diastolic dysfunction using mitral inflow and mitral annu-
lar velocity [31], 1 AL patient had normal diastolic func-
tion, 3 had mild (impaired relaxation pattern), 4 had
moderate (pseudonormalization) and 2 had severe
(restrictive) diastolic dysfunction.
There was higher 16-SD% in AL subjects compared to con-
trols (Table 1, Figures 1, 2, see Additional files 1, 2). There
was shorter cycle length in AL subjects compared to con-
trols. There was no correlation between cycle length and
16-SD% (R = -0.2, p = NS). 16-SD% was weakly correlated
with left ventricular mass index (R = 0.45, p = 0.04). There
was no correlation between 16-SD% and left ventricular
ejection fraction (R = -0.3, p = 0.14).
Intraclass correlation coefficient was 0.625 (p = 0.001) for
intraobserver and 0.606 (p = 0.002) for interobserver dif-
ferences in 16-SD%. The ICC together with the Bland-Alt-
man analysis (Figure 3) show good reproducibility of 16-
SD% measurements. The Bland-Altman plot further
shows better agreement in the measurement at lower 16-
SD% values.
Discussion
Light chain amyloidosis is an often fatal disease with
about 2500 new cases per year in the United States [3,32-
35]. Patients with cardiac involvement have the worst out-
comes in the presence of heart failure [3,36]. Amyloid
deposition in the heart leads to ventricular thickening and
impaired relaxation, classically presenting as diastolic dys-
function often with preserved systolic function as meas-
ured by left ventricular ejection fraction [5-8]. Indeed, left
ventricular ejection fraction was found not to be an inde-
pendent risk factor for mortality in this disease [4]. The
elevated mitral annular velocity E' and ratio of transmitral
inflow velocity to mitral annular velocity E/E' together
with increased left atrial size suggest diastolic dysfunction
[27] that is more prominent than conventional measures
of systolic function (mean left ventricular ejection fraction
58.6 ± 2.8%) in our cohort of AL subjects.
Heart failure is an important cause of morbidity and mor-
tality in AL amyloidosis. There is increasing recognition
that timing of regional ventricular contraction or ventricu-
lar synchrony is important in the development of cardiac
dysfunction and heart failure. Both interventricular and
intraventricular dyssynchrony reduce ventricular effi-
ciency and performance [11]. Treatment of dyssynchrony
with cardiac resynchronization therapy has been shown
to improve survival, reduce heart failure symptoms and
improve quality of life [12,13,37-39]. 3D echocardiogra-
phy is a recent advance in the volumetric assessment of
left ventricular function and software allows the quantifi-
cation of the dispersion of timing to peak systole among
the different ventricular regions, a measure of intraven-
tricular dyssynchrony. Early studies demonstrate that dys-
synchrony measured by the dispersion of systolic timing
among the 16 segments (16-SD%) is associated with
systolic dysfunction [11,15]. In addition to quantifying
the temporal relationship among segments, 3D echocar-
diography also allows acquisition that does not require
correct acquisition axis. In the current study, significant
dyssynchrony was demonstrated in AL subjects. The pres-
Table 1: Echo parameters in AL and healthy subjects.
Control AL p-value
LVEF (%) 62.4 ± 0.6 58.6 ± 2.8 NS
Anteroseptal thickness (cm) 0.97 ± 0.1 1.62 ± 0.5 0.01
LVMI (g/m2) 125.0 ± 48 179.3 ± 79 0.08
LAVI (mL/m2) 25.7 ± 4.8 39.6 ± 16.9 0.009
Cycle length (ms) 1060 ± 166 752 ± 211 0.002
16-SD% (%) 1.67 ± 0.87 5.93 ± 4.4 0.003Cardiovascular Ultrasound 2008, 6:40 http://www.cardiovascularultrasound.com/content/6/1/40
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ence of dyssynchrony in the setting of relatively preserved
LV ejection fraction in the AL group suggests that systolic
dysfunction may occur earlier than previously recognized
and that amyloid deposit in the heart, although diffuse in
distribution [40], still result in regional contractile dys-
function. The study points to the potential of 3D echocar-
diography to detect early changes of left ventricular
systolic dysfunction in AL amyloidosis that might not oth-
erwise be detected by conventional measures of systolic
function. The degree of dyssynchrony is correlated with
left ventricular mass index suggesting that 16-SD% abnor-
mality may be an early indication of cardiac amyloid dep-
osition.
The current finding needs to be related to the recent study
of Bellavia, et al. [14] that utilized 2-dimensional tissue
Doppler imaging to assess regional dyssynchrony. In this
study involving AL amyloid patients with relatively pre-
served left ventricular systolic function, they found that
patients with less advanced cardiac involvement (ven-
tricular thickness < 1.1–1.2 cm and without restrictive fill-
ing pattern) had significantly higher standard deviation of
timing of segmental longitudinal and radial strain signify-
ing regional dyssynchrony compared to age and sex-
matched controls. However, patients with advanced car-
diac involvement (ventricular thickness > 1.1–1.2 cm or
restrictive filling pattern) surprisingly had reduced
regional dyssynchrony. Although the thickness of the ven-
tricle is consistent with advanced classification in most of
our subjects using Bellavia's thickness criteria, most of our
subjects had mild-moderate dysfunction (70%) with only
20% having restrictive filling pattern. It is possible there-
fore, that our patients are more closely related in degree of
16-SD% Figure 2
16-SD%. 16-SD% as a measure of regional ventricular dys-
synchrony was significantly higher in AL compared to control 
subjects.
3D echocardiographic analysis of segmental left ventricular volume change Figure 1
3D echocardiographic analysis of segmental left ventricular volume change. A and B. A represents data from a 
healthy subject and B represents data from AL subject. Top panel shows 16 segments analyzed (excludes apex) with solid cast 
representing endsystolic volume and surrounding grid cast representing beginning systole (or end-diastole) volume. The bot-
tom panel shows the regional volume expressed in proportion to end-diastolic volume with time during the cardiac cycle. In 
these 2 examples, the dispersion of timing of endsystole is narrower in A compared to B.Cardiovascular Ultrasound 2008, 6:40 http://www.cardiovascularultrasound.com/content/6/1/40
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disease to the no-advanced group in that study. Our sam-
ple size is too small to compare more advanced versus less
advanced disease. However, 3D echocardiography is the-
oretically superior to 2-dimensional based techniques in
assessing regional dyssynchrony if data is acquired in 1
cardiac cycle as it allows simultaneous measurement of
systolic timing in all 16 segments versus non-simultane-
ous sequential determination in different views for 2-D
based methods. Differences in systolic timing of segments
taken at different time points may not only be due to
regional dyssynchrony but may also be affected by beat to
beat variation in cycle length and systolic timing. It
remains to be seen whether hypersynchronization would
be also observed in advanced cardiac amyloid patients
using 3-dimensional echocardiography.
The 3D echocardiographic method of assessing ventricu-
lar dyssynchrony appears to have good, although not
excellent, agreement when measured by the same or dif-
ferent observers based on intraclass correlation coefficient
and Bland-Altman analysis. The reliability of this tech-
nique for use in AL amyloidosis subjects needs to be vali-
dated in a larger number of subjects. In future studies,
comparing the presence and degree of dyssynchrony
between amyloid subjects and other benign conditions
presenting with ventricular thickening such as hyperten-
sion may be useful in determining whether this novel
measure is clinically useful in the early diagnosis of AL
cardiac amyloidosis.
Conclusion
Intraventricular segmental dyssynchrony is demonstrated
for the first time in light chain amyloidosis subjects com-
pared to healthy controls with higher temporal pattern of
dispersion of regional volume systolic change (16-SD%)
on 3D echocardiography. Since left ventricular ejection
fraction is relatively preserved in this cohort of AL sub-
jects, regional intraventricular dyssynchrony by 3D
echocardiography is a novel technique that may allow ear-
lier detection of systolic dysfunction in this disease condi-
tion.
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Bland-Altman plot for intraobserver and interobserver limits of agreement for 16-SD% Figure 3
Bland-Altman plot for intraobserver and interobserver limits of agreement for 16-SD%. Differences in measure-
ment are plotted against average of two measurements for intraobserver (left) and interobserver (right). There is overall good 
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to the cardiac cycle length. Note that the timing of peak systolic volume 
change occurs almost simultaneously in this normal control subject.
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Additional file 2
AL patient. A similar 3D echocardiographic acquisition as in Movie 1 but 
in an AL patient. Note that there is less synchronous regional motion. Bot-
tom panel shows the dispersion of timing of peak systolic volume change 
in the different segments.
Click here for file
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